Immatics (IMTX) Competitors

Immatics (NASDAQ:IMTX) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Do institutionals and insiders believe in IMTX or RGNX?

64.4% of Immatics shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 3.3% of Immatics shares are held by company insiders. Comparatively, 13.1% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has better earnings and valuation, IMTX or RGNX?

Immatics has higher earnings, but lower revenue than REGENXBIO. Immatics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$58.44M	14.86	-$104.98M	-$1.30	-7.89
REGENXBIO	$90.24M	8.75	-$263.49M	-$6.03	-2.67

Do analysts recommend IMTX or RGNX?

REGENXBIO has a consensus price target of $38.45, suggesting a potential upside of 138.70%. Given REGENXBIO's higher possible upside, analysts clearly believe REGENXBIO is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
REGENXBIO	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Does the media prefer IMTX or RGNX?

In the previous week, REGENXBIO had 7 more articles in the media than Immatics. MarketBeat recorded 9 mentions for REGENXBIO and 2 mentions for Immatics. Immatics' average media sentiment score of 0.44 beat REGENXBIO's score of 0.23 indicating that Immatics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor IMTX or RGNX?

REGENXBIO received 398 more outperform votes than Immatics when rated by MarketBeat users. However, 71.43% of users gave Immatics an outperform vote while only 65.89% of users gave REGENXBIO an outperform vote.

Company	Underperform	Outperform
Immatics	Outperform Votes 25 71.43%	Underperform Votes 10 28.57%
REGENXBIO	Outperform Votes 423 65.89%	Underperform Votes 219 34.11%

Is IMTX or RGNX more profitable?

Immatics has a net margin of -179.67% compared to REGENXBIO's net margin of -291.99%. Immatics' return on equity of -43.58% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-179.67%	-43.58%	-22.38%
REGENXBIO	-291.99%	-68.18%	-39.95%

Which has more risk and volatility, IMTX or RGNX?

Immatics has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

Summary

Immatics and REGENXBIO tied by winning 9 of the 18 factors compared between the two stocks.